Vitamin E succinate induces Fas-mediated apoptosis in estrogen receptor-negative human breast cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Estrogen receptor-negative breast cancers are aggressive and often resistant to therapy.
• Vitamin E succinate (VES), a derivative of vitamin E (alpha-tocopherol), is being investigated for its anti-cancer properties.
• The Fas pathway plays a critical role in programmed cell death (apoptosis).

Purpose of the Study:

• To investigate the mechanism by which Vitamin E succinate (VES) induces apoptosis in estrogen receptor-negative human breast cancer cells.
• To determine the role of the Fas pathway in VES-mediated cell death.
• To explore the potential clinical application of VES in treating aggressive breast cancers.

Main Methods:

• Treatment of human breast cancer cell lines (MDA-MB-231 and SKBR-3) with Vitamin E succinate (VES).
• Analysis of protein levels and cell surface expression of Fas receptor (Fas; APO-1/CD-95) and Fas ligand (Fas-L).
• Inhibition studies using Fas-neutralizing antibodies and Fas-L antisense oligonucleotides.

Main Results:

• VES inhibited growth and induced apoptotic cell death in estrogen receptor-negative breast cancer cells.
• VES treatment increased total protein levels and cell surface expression of Fas and Fas-L.
• Blocking the Fas pathway with antibodies or antisense oligonucleotides abrogated VES-induced apoptosis.

Conclusions:

• Fas signaling is a key mediator of Vitamin E succinate (VES)-induced apoptosis in human breast cancer cells.
• VES demonstrates potential as a therapeutic agent for aggressive breast cancers, including those resistant to antiestrogen therapy.